Table 2 Summary of treatments and outcomes in symptomatic SISMAD patients
|  | Conservative group (n = 15) | Endovascular group (n = 27) | p value |
|---|---|---|---|
Median hospital stay (IQR), days | 9 (3, 15) | 9 (7, 11) | 0.813 |
Blood pressure control, n (%) | 10 (66.7) | 13 (48.1) | 0.337 |
Bowel rest, n (%) | 8 (53.3) | 18 (66.7) | 0.511 |
Median fasting time (IQR), days | 1 (0, 6) | 1 (0, 5) | 0.818 |
Anticoagulation therapy, n (%) | 9 (60.0) | 20 (74.1) | 0.488 |
Antiplatelet therapy, n (%) | 9 (60.0) | 23 (85.2) | 0.128 |
Technical success, n (%) | NA | 23 (85.2) | / |
Stent placement, n (%) | NA | 23 (85.2) | / |
Balloon angioplasty, n (%) | NA | 7 (25.9) | / |
Outcomes | |||
 Symptom resolution, n (%) | 14 (93.3) | 26 (96.3) | 1.000 |
aComplications, n (%) | 0 | 1 (3.7) | 1.000 |
 Mortality, n (%) | 0 | 0 | 1.000 |
bFollow-up | |||
 Median time (IQR), months | 25 (8, 55) | 29 (17, 48) | 0.333 |
 Symptomatic, n (%) | 6 (42.9) | 1 (4.8) | < 0.001 |
 Intestinal necrosis, n (%) | 0 | 0 | 1.000 |
 Underwent endovascular intervention, n (%) | 4 (28.6) | NA | / |
 Secondary endovascular intervention, n (%) | NA | 1 (4.8) | / |
 Disease unrelated mortality, n (%) | 0 | 1 (4.8) | 1.000 |
cComplete remodeling in the SMA, n (%) | 1 (9.1) | d13 (86.7) | < 0.001 |